New subgroup analyses from landmark phase 3 aspen study of brensocatib in patients with bronchiectasis demonstrate consistency with positive overall trial population results

—data presented at the chest 2024 annual meeting— bridgewater, n.j. , oct. 8, 2024 /prnewswire/ -- insmed incorporated (nasdaq: insm), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the phase 3 aspen study, a global, randomized, double-blind, placebo-controlled phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis.
INSM Ratings Summary
INSM Quant Ranking